
Lymphoma and CAR T–Related Renal Injury: Assessing the Risks
'Our study is the largest to date examining renal toxicity in CD19 CAR T–treated lymphoma patients,' senior author Roni Shouval, MD, PhD, director of the Precision Cellular Therapy Laboratory at Memorial Sloan Kettering (MSK) Cancer Center, New York City, said in an interview.
While the findings show no link between baseline kidney function and the development of AKI, ultimately, 'hypoalbuminemia may be a better flag for AKI risk and a prompt for closer monitoring or proactive interventions such as fluid management and nephrotoxin avoidance,' Shouval said.
The study was published in March in Haematologica .
CAR T-cell therapy is known to provide durable disease remission in relapsed or refractory non-Hodgkin lymphoma, including in the disease subsets of large B-cell lymphoma (LBCL) and mantle cell lymphoma (MCL).
While the common treatment-related toxicities of cytokine release syndrome (CRS) and immune effector cell–associated neurologic syndrome (ICANS) are well documented, less has been reported regarding AKI treatment–related effects and outcomes.
The US Food and Drug Administration Adverse Event Reporting System (FAERS) AKI Reports
To investigate, Shouval, first author Alexander P. Boardman, MD, also of MSK, and colleagues first screened data from the FAERS database, identifying 5912 patients who had adverse events related to CD19 CAR T-cell therapy reported between January 2017 and September 2022.
The patients had a median age of 62 years, and the most common CAR T-cell therapies utilized were axi-cel (n = 3526 patients), followed by tisa-cel (n = 1780), liso-cel (n = 178), and brexu-cel (n = 428).
The main indications for CAR T-cell treatment were non-Hodgkin lymphoma (88%) and acute lymphoblastic leukemia (11%).
Overall, 211 (3.6%) patients developed AKI that was determined to have a primary etiology of CD19 CAR T-cell therapy, with no significant differences based on age, sex, event year, type of CD19 CAR T-cell therapy, or indication.
Of note, AKI was more common among patients treated with CD19 CAR T-cell therapy than among all other patients with cancer in the FAERS database (age- and sex-adjusted reporting odds ratio [ROR], 1.72).
AKI developed at a median of 2.5 days post-infusion, and patients with AKI were more likely to have had concurrent CRS than those with other CAR T-cell reports not involving AKI (64% vs 50%; P < .001).
The rates of life-threatening illness (22.75% vs 8.00%) and mortality (49% vs 23%; P < .001 for all) were higher among patients with AKI than among those with other CD19 CAR T-cell reports not involving AKI.
'In the FAERS dataset, we observed a disproportionately high reporting of AKI among CAR T recipients compared to other oncology patients, reinforcing that renal toxicity is a consistent safety signal on a population level,' Shouval said.
A Closer Look
In a subsequent single-center analysis, the authors identified 399 patients with relapsed or refractory non-Hodgkin lymphoma treated with CD19 CAR T-cell therapy at MSK Cancer Center between April 2016 and December 2023.
Of the patients, 84% had LBCL, 11% had MCL, and 5% had non-LBCL.
Their median age was 66 years, and the most common treatments included were axi-cel (46%), tisa-cel (20%), liso-cel (29%), and brexu-cel (5%).
Of note, patients' pre-lymphodepletion estimated glomerular filtration rate (eGFR) was not associated with overall or progression-free survival, CRS grade ≥ 2, ICANS grade ≥ 2, or neutropenia.
'Thus, baseline renal function was not significantly associated with efficacy or toxicity endpoints,' the authors reported.
AKI, Kidney Outcomes
From the time of CAR T-cell infusion to day 100, AKI of any grade was reported among 39 (10%) of the MSK patients, with only a small percentage (5%) having grade ≥ 2 AKI.
The majority of AKI cases (71.8%) were attributed to prerenal factors; 14 cases occurred concurrently with CRS.
For survival outcomes, those developing AKI within 100 days of treatment had significantly lower progression-free survival (hazard ratio [HR], 2.63; P < .001) and overall survival (HR, 3.36; P < .001) than those without AKI.
And among those with AKI grade ≥ 2, progression-free survival was significantly lower (HR, 3.14; P < .001), as was overall survival (HR, 4.18; P < .001).
Low Albumin, Inflammatory Markers Linked to Increased AKI Risk
Notably, after a multivariate adjustment, serum albumin level prior to lymphodepletion was a significant risk factor for AKI (HR, 0.15; P < .001).
In addition, higher levels of inflammatory markers, specifically serum interleukin 6 (HR, 1.74; P = .008) and tumor necrosis factor alpha (HR, 2.23; P < .001), on day 0, just prior to CAR T-cell infusion, were significantly associated with the risk for AKI
'Intriguingly, we are the first to determine that hypoalbuminemia is strongly associated with risk of AKI after CAR T-cell therapy,' the authors reported. 'Hypoalbuminemia emerged as an even more robust independent predictor of AKI than baseline eGFR,' Shouval added.
'In clinical terms, we believe hypoalbuminemia is surrogate for frailty and possibly systemic inflammation,' he said. 'Therefore, patients with low albumin should be recognized as high risk for renal complications.'
'Overall, we find that most AKI events after CAR T-cell infusion are of grade 1 and that most patients recover from these events within 3 months,' the authors wrote.
However, in looking at the eGFR and AKI outcomes together, Shouval concluded that 'these data position AKI as both a clinically meaningful and prognostically significant complication, deserving greater attention in the CAR T risk-benefit assessment.'
Findings Point to a 'Cytokine-Driven Phenomenon'
Commenting on the research, Michael D. Jain, MD, PhD, medical director of the Immune and Cellular Therapy Program at the H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, noted that the findings underscore that CAR T-cell therapy 'is really a cytokine-driven phenomenon rather than related to comorbidities that cause baseline chronic kidney disease [CKD].'
He added that low albumin, often a marker of inflammation/cytokines, 'might contribute to AKI because it affects intravascular volume and thus blood flow to the kidney.'
Jain agreed that the risk for AKI and other complications from CAR T is 'related more to tumor burden and inflammation than to baseline renal dysfunction.'
'In our center, we have protocols to give CAR T cells to patients who are on dialysis and believe we can safely deliver their therapy,' he noted.
A Word of Caution Re CKD
In a smaller study of 155 patients treated with CAR T-cell therapy for relapsed/refractory LBCL, a history of CKD was, contrarily, found to indeed be associated with AKI on a multivariate analysis (RR, 2.7; P = .04).
However, while in Shouval's study, most patients who had low eGFR (< 60 mL/min/1.73 m2) received either liso-cel or tisa-cel, in this study, the majority of patients received axi-cel.
Based on that, 'I would offer caution [using CAR T-cell therapy] in those with CKD, especially in those receiving axi-cel,' senior author Narendranath Epperla, MD, of the James Cancer Hospital, The Ohio State University, Columbus, Ohio, said in an interview.
He added, however, that Shouval's research importantly 'highlights a clinically relevant yet understudied complication of CAR-T that would aid clinicians in decision-making and counseling peri-CAR T.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Fast Company
9 hours ago
- Fast Company
Ignoring GenAI is risky for businesses
Sometimes one bad apple can spoil the whole bushel. Generative AI (GenAI) seems to have gotten a bit of that reputation—a few high-profile, epic fails in a range of industries have made many organizations limit internal use of this technology, and sometimes even ban it to reduce business risk. The reality is, despite the inherent risk of hallucinations and inaccuracies, GenAI is rapidly being adopted in industries that hinge on precision and certainty, such as pharmaceutical research, medical diagnostics and legal —industries in which time to insight also drives competitive advantage. Let's take sales as a generic example. Proper use of GenAI tools can speed time to insight significantly, allowing a sales team to improve the quality of their prospects, create meeting summaries and action items, and quickly glean insight from the mountains of client and prospect data that already exist in enterprise systems. This team has a distinct advantage over a competitor that uses manual processes or non-GenAI tools for opportunity analysis. Thus, in sales, the business risk GenAI poses is opportunity risk: the revenue opportunities one loses out on by not using this technology. Let's dive into that. GenAI opportunity risk Broadly speaking, opportunity risk can be thought of as 'the potential loss or missed opportunity that an organization faces by not taking advantage of favorable circumstances or potential benefits.' For companies that ignore GenAI, the resulting opportunity risk can manifest in a wide range of significant ways. Here are three examples of GenAI opportunity risk, from a macro level down to a very individual, in-the-moment view. Drug development research labs risk losing revenue. Drug development research labs are using GenAI to digitally design drug molecules, which are translated in a high-speed automated lab into physical molecules and tested for interaction with target proteins. The test results are used to improve the next design iteration, speeding the overall process. These development labs, which typically partner with pharmaceutical giants, aim to reduce from seven years to four years the time it typically takes to get a new drug to the pre-clinical trial stage—a critical chunk of the $1 billion and 10 to 15 years required, on average, to develop a new drug. The stakes in the global pharmaceutical market are incredibly high, and speed to market can have an enormous impact on revenues. Pharmaceutical companies that don't take advantage of advanced GenAI technologies, either internally or through a development partner, are at a distinct competitive disadvantage and may risk losing billions in future revenues. Software companies are increasingly using GenAI to write code. About 30% of new code at Google and Microsoft is AI-generated, while Meta recently said that AI will take over half of the company's software development within the next year. These BigTech companies, as well as many startups, are finding ways for GenAI to accelerate their pace of software development. Competitors that don't use GenAI to dramatically improve their software development practice face the very sobering opportunity risk of simply being out innovated in the market. Legal teams risk losing a competitive advantage. Legal teams that use GenAI tools in the discovery phase of a legal matter can accelerate their time to insight in ways that are nothing short of game-changing. For example, one Am Law 100 firm used a GenAI tool to review 1 26,000 documents in a government investigation. In doing so, the firm slashed document review time by 50% to 67%, with one quarter of the personnel that a project of this size would typically require. The review achieved accuracy rates of 90% or higher, with performance at or above the firm's benchmark metrics for first-level attorney reviewers. In the moment, this breakthrough gave the team more time to debate the merits of a potential piece of evidence instead of blindly clicking through endless documents. Strategically, the two-thirds reduction in document review time and the 75% reduction in associated headcount gave the law firm an invaluable amount of additional time to develop its case prior to appearing in court. For legal teams that don't use GenAI tools to supercharge their eDiscovery efforts, it's easy to envision any lawyer's nightmare scenario: arriving at court to face off against an adversary who's had far more time to develop their case, based on a solid foundation of facts culled from discovery documents. Who wants to risk that happening?


Health Line
9 hours ago
- Health Line
What Conditions Can Be Misdiagnosed as Psoriasis?
Key takeaways Psoriasis can be difficult to diagnose because its symptoms are similar to those of other skin conditions, and it may present differently on different skin tones. If you suspect you've been misdiagnosed with a different skin condition, a dermatologist can perform a thorough skin exam, possibly including a biopsy, to accurately diagnose psoriasis. While there is no cure for psoriasis, an accurate diagnosis allows for the creation of an appropriate treatment plan to manage symptoms and monitor for related health conditions. Understanding the basics Getting the correct diagnosis as soon as possible is key when you have ongoing skin irritation. Psoriasis is a lifelong condition but can be managed with the right treatment plan. Because psoriasis shares characteristics with other skin conditions, a doctor might not always identify it when they first perform an examination. Here's more about psoriasis, its symptoms, and what to do if you think you've been misdiagnosed. What is psoriasis? Psoriasis is a common autoimmune disease in the United States. Approximately 7.5 million adults age 20 years or older have psoriasis — a 3% prevalence rate (occurrence of a condition). By race and ethnicity, the prevalence rates are: 3.6 percent of white people 3.1 percent of non-Hispanic, including multiracial people 2.5 percent of Asian people 1.9 percent of Hispanic, including Mexican American people 1.5 percent of Black people But this data may not tell the entire story. Patients of color may be disproportionately undertreated and misdiagnosed. This is because psoriasis isn't always recognized on darker skin tones as it is for those who have lighter skin tones. Psoriasis typically begins to appear in people between ages 15 and 35, but it can start at any age. Many people may carry the genetic predisposition to develop psoriasis, but it does not always express itself. Instead, different triggers can unexpectedly cause the symptoms to surface. The triggers can include: stress injuries medications infections illnesses diet What are the symptoms of psoriasis? Psoriasis can manifest in different ways and varying severities. It can also affect different parts of your body. The primary symptoms can include: patches of inflamed or discolored skin gray or silvery scales on the skin dry skin cracked skin bleeding skin itching soreness pitted nails thick nails stiff joints inflamed joints Psoriasis rashes can present differently based on skin types: on light or fair skin tones, psoriasis tends to be pink or red with a silvery-white scale on medium skin tones, psoriasis appears as salmon-colored with a silvery-white scale on dark skin tones, psoriasis can be violet with a gray scale, or it can appear dark brown and be difficult to see Types of psoriasis Beyond basic symptoms, there are many types of psoriasis: Plaque psoriasis Plaque psoriasis is the most common of all types. You could experience the general symptoms on different parts of your body. You may even notice patches inside your mouth and nose. Nail psoriasis Nail psoriasis affects the fingernails and toenails. They may become loose or even fall off with time. Scalp psoriasis Scalp psoriasis is also localized. The scales reach beyond your hairline. You may notice flaky skin after scratching your scalp. Guttate psoriasis Guttate psoriasis can happen after bacterial illnesses, such as strep throat, and it usually affects children and young adults. The sores you'll find with this type are shaped like water drops and are concentrated on the following: arms legs scalp trunk Inverse psoriasis Inverse psoriasis creates areas of smooth, colored rash in skin folds, especially: under the armpits around the breasts around the groin on the genitals Pustular psoriasis Pustular psoriasis is uncommon, but it may give you more than just skin symptoms. You'll typically get a fever, chills, and diarrhea with the red rash. Blisters filled with pus accompany the patches or irritation. Erythrodermic psoriasis Erythrodermic psoriasis is the least common type of psoriasis. It causes large areas of your skin to peel, itch, and burn. How is psoriasis diagnosed? A primary care doctor may refer you to a dermatologist for a diagnosis of psoriasis. They'll likely ask whether you have a family history of the disease and ask about different triggers that may have set off your symptoms. From there, they will perform a physical examination that includes a complete skin exam. They will look at your skin for signs of psoriasis. In some cases, you may need to undergo a skin biopsy. Your doctor will use a general anesthetic and obtain a small sample of your skin to study under a microscope. If the sample exhibits characteristics of psoriasis histologically, this is often enough information to make the diagnosis. There is limited research and information about managing and diagnosing psoriasis in BIPOC (Black, Indigenous, and People of Color). This means thatpatients of color may be disproportionately misdiagnosed. What else could this skin condition be? Several skin conditions share characteristics with psoriasis. Knowing their symptoms, causes, and other characteristics may help you identify your own skin issues. Seborrheic dermatitis If your rash is concentrated on oily parts of your skin, it might be seborrheic dermatitis. With this condition, you may experience itchy and scaly skin on your upper chest and face. You can also develop dandruff on your scalp. Lichen planus The immune system can trigger lichen planus. The lesions you'll see are violaceous and flat. These can often form rows on your arms and legs. You may also experience itching or burning. White lines may appear over the irritated areas. Ringworm Rashes that have a ring shape might be caused by ringworm or dermatophytosis. This fungal infection affects the top layer of your skin. You can contract the infection through soil carrying the fungi or close contact with people who have ringworm. Pityriasis rosea If you have pityriasis rosea, you'll likely get a single spot in the first stage. This skin condition is common and may eventually take on the appearance of pine branches. You'll typically notice the rash on your stomach, chest, or back before it spreads. Other skin conditions Psoriasis can also be confused with: Do you think you've been misdiagnosed? If you're concerned about being misdiagnosed, consider seeing a dermatologist. You may even want to request a skin biopsy to get a more definitive diagnosis. Also, you might try to think of information that may help with identification, such as: Do I have a family history of psoriasis? How long have I noticed symptoms? Where is the affected area located? Are there any triggers that might have produced my symptoms? If so, what are they? Do I have signs that align with any of the look-alike conditions? Are there any other symptoms, like swollen joints, bothering me? If you still aren't satisfied after your appointment, seek a second opinion. You can ask a primary care doctor for a referral to a dermatologist. A dermatologist is usually your best bet for getting the most accurate skin condition diagnosis. Treatment and complications Treating psoriasis involves healing the areas of discomfort and slowing skin growth. Depending on your symptoms and the type of psoriasis, your doctor may try different topical therapies, like topical vitamin D or corticosteroids. Phototherapy, also known as ultraviolet light therapy, can also be effective in certain cases. More advanced flare-ups may be treated with medications like methotrexate, cyclosporine or tacrolimus, biologics, acitretin, or apremilast. Before prescribing anything, your doctor will consider the severity of your condition, your medical history, and potential drug interactions. There isn't a cure for psoriasis, but knowing you have it may help a doctor diagnose other health issues. People with psoriasis are at a higher risk of developing other conditions such as psoriatic arthritis, metabolic syndrome, and cardiovascular disease.


Newsweek
21 hours ago
- Newsweek
VA Announces Improved Funding For Veteran Health Care
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The Department of Veterans Affairs (VA) has announced an $800 million boost in funding for infrastructure improvements across its health care facilities. On Wednesday, the VA revealed plans to realign an additional $800 million to the Veterans Health Administration's Non-Recurring Maintenance (NRM) program during the current fiscal year. Why It Matters Across the U.S, there are 1,380 health care facilities, including 170 VA Medical Centers and 1,193 outpatient sites, serving over 9.1 million veterans enrolled in the VA health care program. The investment comes amid efforts to modernize VA medical facilities, strengthen accountability in spending, and ensure that veterans receive quality, timely care. The funding increase aligns with a broader push in Congress and the federal government to fully support veterans' health programs, improve oversight, and reduce waste within the VA system. What To Know According to a press release, these funds will address urgent needs across VA facilities, covering projects such as modernization of boiler and chiller systems, upgrading electric infrastructure, improving elevators, updating heating, ventilation, and air conditioning (HVAC) systems, enhancing fire safety through sprinklers and alarms, renovating clinical and support spaces, and supporting the Electronic Health Record Modernization initiative. VA Health Center sign in Louisville, Kentucky, July 2019. VA Health Center sign in Louisville, Kentucky, July 2019. GETTY Numerous changes have been made to VA health and support programs throughout 2025. Earlier this year, the VA confirmed that to help reduce wait times and administrative bottlenecks, those receiving its healthcare services will no longer need a second VA physician to review and approve their eligibility to receive non-VA health care. In May, the VA announced that some $52 million in funding is now available to support community-based organizations focused on suicide prevention and emergency clinical services for veterans at risk of taking their own life. In a 2024 report, the VA revealed there were 6,407 suicides among Veterans in 2022, the latest year for which data is available. More recently, on Tuesday, the VA announced a new partnership with the Centers for Medicare and Medicaid Services (CMS) aims to prevent duplicate health-care billings for veterans. The VA has identified $106 million in duplicate payments to providers over the last six years and as a result has begun seeking recovery from overpaid providers this month. What People Are Saying VA Secretary Doug Collins said in the press release: "This is another step forward in our efforts to make VA work better for the Veterans, families, caregivers, and survivors we are charged with serving. Improved facilities, equipment, and infrastructure help improve care for Veterans, and these additional funds will enable VA to achieve that goal." What Happens Next The federal department said the new funding brings total NRM program spending for fiscal year 2025 to $2.8 billion—approximately $500 million more than the previous year, the VA reports.